Table 1.
Clinical features of the studied cohorts.
| Variable | Mexican*n (%) | TARGET**n (%) | |
|---|---|---|---|
| Sex | Female | 43 (51.8) | 89 (50.3) |
| Male | 40 (48.2) | 88 (49.7) | |
| Age (years) | 1<10 | 56 (67.5) | 117 (66.1) |
| ≥10 | 27 (32.5) | 60 (33.9) | |
| WBC at diagnosis (×109/L) | <10 | 32 (38.6) | 41 (23.2) |
| 10–49.99 | 33 (39.8) | 70 (39.6) | |
| 50–99.99 | 8 (9.6) | 36 (20.3) | |
| >100 | 10 (12) | 30 (16.9) | |
| BM blasts (%) at diagnosis | <90 | 7 (8.4) | NR |
| ≥ 90 | 76 (91.6) | NR | |
| Common gene rearrangements | ETV6/RUNX1 | 7 (8.4) | 18 (10.2) |
| TCF3/PBX1 | 7 (8.4) | 19 (10.8) | |
| BRC/ABL1 | 1 (1.2) | 4 (2.25) | |
| MLL/AF4 | 1 (1.2) | 4 (2.25)° | |
| TCF3/HLF | ND | 2 (1.1) | |
| iAMP21 | ND | 6 (3.4) | |
| Hyperdiploidy | ND | 45 (25.4) | |
| Negative | 67 (80.8) | 79 (44.6) | |
| NCI risk classification | Standard risk | 20 (24.1) | NR |
| High risk | 63 (75.9) | NR | |
| MRD at day 29 | <0.01% | ND | 102 (57) |
| >0.01% | ND | 72 (41) | |
| Relapse | Yes | 20 (24.1) | 141 (79.7) |
| No | 63 (75.9) | 36 (20.3) | |
| Death | Yes | 18 (21.7) | 101 (57) |
| No | 65 (78.3) | 76 (43) | |
WCB, white blood cells; BM, bone marrow; NCI, National Cancer Institute, NIH, USA; MRD, minimal residual disease; ND, no determined; NR, non-reported. ° Including other MLL rearrangements. *N = 83, **N = 177.